Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Next Previous
X
Search
Trial Profile

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riluzole (Primary)
  • Indications Social phobia
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 22 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2018 According to a Biohaven Pharmaceutical Holding Company media release, the FDA (in Nov 2018) has agreed to a modification of the trials primary endpoint, the Scale for Assessment and Rating of Ataxia (SARA) as an acceptable registrational endpoint.
    • 16 Aug 2018 According to Biohaven Pharmaceuticals media release, the company expects to present additional results from this trial at upcoming scientific meetings over the next year. Based upon these trial results, Biohaven plans to expand its glutamate modulating platform development program to include the treatment of Generalized anxiety disorder (GAD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top